Senguttuvan, R.N.; Wei, C.; Raoof, M.; Dellinger, T.H.; Wang, E.W.
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. J. Clin. Med. 2023, 12, 3839.
https://doi.org/10.3390/jcm12113839
AMA Style
Senguttuvan RN, Wei C, Raoof M, Dellinger TH, Wang EW.
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. Journal of Clinical Medicine. 2023; 12(11):3839.
https://doi.org/10.3390/jcm12113839
Chicago/Turabian Style
Senguttuvan, Rosemary Noel, Christina Wei, Mustafa Raoof, Thanh H. Dellinger, and Edward Wenge Wang.
2023. "Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma" Journal of Clinical Medicine 12, no. 11: 3839.
https://doi.org/10.3390/jcm12113839
APA Style
Senguttuvan, R. N., Wei, C., Raoof, M., Dellinger, T. H., & Wang, E. W.
(2023). Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. Journal of Clinical Medicine, 12(11), 3839.
https://doi.org/10.3390/jcm12113839